Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial

The dynamic prediction provided by partly conditional models offers valuable insights into the treatment discontinuation risks using PRO data collected over time from clinical trial participants. This tool may benefit healthcare professionals in identifying patients at high risk of premature treatment discontinuation and support interventions to prevent potential discontinuation.

• Publication year

  2023

• Venue

  Cancer Prevention Research

• Publication date

  2023-09-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1940-6207.CAPR-23-0216PMID 37756580PMCID 10618646
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35

  2021cited by this paper
• Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

  2019cited by this paper
• On longitudinal prediction with time‐to‐event outcome: Comparison of modeling options

  2017cited by this paper
• The use of repeated blood pressure measures for cardiovascular risk prediction: a comparison of statistical models in the ARIC study

  2016cited by this paper
• Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

  2016cited by this paper
• Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.

  2016cited by this paper
• Fallacies of last observation carried forward analyses

  2016cited by this paper
• Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls

  2009cited by this paper
• Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women

  2008cited by this paper
• Quantifying the Predictive Performance of Prognostic Models for Censored Survival Data with Time‐Dependent Covariates

  2008cited by this paper
• A Stepwise AIC Method for Variable Selection in Linear Regression

  2007cited by this paper
• The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer.

  2005cited by this paper
• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper
• Partly Conditional Survival Models for Longitudinal Data

  2005cited by this paper
• Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker

  2000cited by this paper
• Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

  1996cited by this paper
• Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale).

  1994cited by this paper
• Index for rating diagnostic tests

  1950cited by this paper
• The CES-D Scale: A Self-Report Depression Scale for Research in the General Population — Source link

  year unknowncited by this paper

• Musculoskeletal symptoms associated with aromatase inhibitors in the treatment of early breast cancer: A scoping review of risk factors and outcomes

  2025cites this paper
• Genitourinary syndrome of menopause (GSM): recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).

  2025cites this paper
• National Cancer Institute Cancer Treatment Tolerability Consortium: Current status and future directions

  2025cites this paper
• Analyses of adverse events and patient‐reported outcomes with the toxicity index in cancer clinical trials

  2025cites this paper